Drug WatchKetoacidosis Possible from Some Type 2 Diabetes DrugsAschenbrenner, Diane S. MA, RN Author Information Diane S. Aschenbrenner was previously the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: diane. [email protected]. AJN, American Journal of Nursing 115(9):p 22, September 2015. | DOI: 10.1097/01.NAJ.0000471241.53821.ff Buy Metrics Abstract Sodium–glucose cotransporter-2 (SGLT2) inhibitors, used to treat type 2 diabetes, may lead to diabetic ketoacidosis, ketoacidosis, or ketosis early in drug therapy. The class includes canagliflozin, dapagliflozin, and empagliflozin. Patients beginning treatment with an SGLT2 inhibitor should be instructed to be alert for tachypnea or hyperventilation, anorexia, abdominal pain, nausea, vomiting, lethargy, or mental status changes. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
